High-Tech CEO
Shipping & Delivery
Our Delivery Time Frames Explained
2-4 Working Days: Available in-stock
14-28 Working Days: On Backorder
Will Deliver When Available: On Pre-Order or Reprinting
We ship your order once all items have arrived at our warehouse and are processed. Need those 2-4 day shipping items sooner? Just place a separate order for them!
Product details
- ISBN 9780367695804
- Weight: 680g
- Dimensions: 156 x 234mm
- Publication Date: 08 Feb 2022
- Publisher: Taylor & Francis Ltd
- Publication City/Country: GB
- Product Form: Paperback
This book examines the impact of CEOs on firm performance and focuses on their role in science-based innovation to answer the question, is it possible to lead highly complex R&D projects and innovation that you do not understand?
Today, science and technology move so fast that even managers of R&D teams can become quickly disconnected from new developments. Similarly, business leaders may be required to lead organisations with technical knowledge beyond their own expertise. How to manage teams and retain respect and influence is a recognised challenge. Filled with insight from managers and CEOs in science and technology organisations, the book unlocks the skills required to balance the leadership and managerial needs of the organisation, motivate the technical teams and drive successful innovation in new product development environments. Due to the vital role played by experts in a chosen field of technical and scientific expertise, the book also describes what these specialists need and expect from their leaders.
The book is required reading for managers in high tech and scientific environments – the CEO, CSO and the R&D manager. It can also be used as a classroom reference book on the management skills required for leading high-tech projects.
Jan Rosier is the ELAN Professor of the Business of Biotechnology at UCD. He holds both a doctorate in pharmaceutical sciences (Ghent University, Belgium) and a doctorate in management (Cranfield School of Management, UK). Prior to his academic appointment, he was instrumental in the development of several new breakthrough drugs and was CEO of a start-up high-tech firm.
